Search
for
Sort by
Research 721–750 of 1000+
- Lipid Profile and 5α-Reductase Inhibition Activity of Proprietary Ultrahigh-Pressure Supercritical Carbon Dioxide and Hexane Saw Palmetto Extracts
- Synthesis and structural characterization of a new dinuclear platinum(III) complex, [Pt<sub>2</sub>Cl<sub>4</sub>(NH<sub>3</sub>)<sub>2</sub>{μ-HN=C(O)Bu<sup>t</sup>}<sub>2</sub>]
- Case Report: Disorder of Sexual Development in a Chinese Crested Dog With XX/XY Leukocyte Chimerism and Mixed Cell Testicular Tumors
- A study of clinical and investigational profile of hirsute women at a tertiary care center in Western India
- Medical Therapies for Treatment of BPH: Special Considerations in Elderly Men
- Overnight loss of pigmented hair in autoimmune autonomic neuropathy treated with IVIg
- Pseudoglucagonoma syndrome secondary to pancreatitis: A case report
- Icariside II inhibits gastric cancer progression by suppressing the Wnt/β-catenin signaling pathway
- Polygenic risk score predicting susceptibility and outcome of benign prostatic hyperplasia in the Han Chinese
- Food Administration and Not Genetic Variants Causes Pharmacokinetic Variability of Tadalafil and Finasteride
- Are ABO/Rh blood groups A risk factor for polycystic ovary syndrome?
- The Multiple Consequences of Obesity
- 46, XY 5-Alpha Reductase Deficiency in a 36-Year-Old Phenotypic Female Patient
- Review of Topical Therapies for Beard Enhancement
- Bilateral nevus comedonicus of the eyelids: An unusual cause of ptosis and ectropion
- A randomized double blind controlled study evaluating efficacy & Safety of vatika enriched coconut hair oil on hair health in women with hair fall and dandruff
- Editorial Comment
- Finasterid in der Behandlung der benignen Prostatahyperplasie
- Comparison of Clinical Efficacy of Finasteride and Dutasteride as 5-alpha Reductase Inhibitor
- Risks Associated with 5α-Reductase Inhibitor Use: Analysis of Adverse Drug Reactions Reported to EudraVigilance
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Case Report: Pulsed electric field treatment of metastatic liver disease demonstrating a possible abscopal response
- Evaluation of a Porcine-Derived Placental Powder Treatment for Skin Wound Healing in an In Vivo Rat Skin Defect Model.
- Combination Therapy for Extensive Tumoral Calcinosis in Juvenile Dermatomyositis
- Optimization of photobiomodulation therapy for spinal cord injury: A review
- Pharmacological Role and Clinical Applications of 5α-Reductase Inhibitors-Review Article for Pharmacists and Healthcare Professionals
- 875 Clinical, Histologic and Immunohistochemical Characterization of Mixed Epithelial and Stromal Tumor of the Seminal Vesicle: A Systematic Review and a Novel Case Report
- Effect of Fenugreek Extract on Testosterone Propionate-Induced Benign Prostatic Hyperplasia